Diagnostic Imaging and Radiopharmaceuticals

Targeted radiopharmaceuticals offer new hope for longer 'healthspans'

AuntMinnie

MARCH 15, 2024

An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care. Precision radiopharmaceuticals accurately target tumors while minimizing damage to healthy tissue. Precision radiopharmaceuticals represent a step toward better, longer lifespans for all.

Radiopharmaceuticals

Radiopharmaceuticals Radiation Disease Diagnostic Imaging

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Imaging Technology

DECEMBER 6, 2023

and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.

Diagnostic

Diagnostic Diagnostic Imaging Clinic Radiopharmaceuticals

What is Radiotheranostics? The Future of Personalised Cancer Diagnosis

Open Medscience

JUNE 22, 2024

Radiotheranostics combines diagnostic imaging and targeted radiotherapy, using radiopharmaceuticals for personalised, precise cancer treatment and improved outcomes. The post What is Radiotheranostics? The Future of Personalised Cancer Diagnosis appeared first on Open MedScience.

Radiopharmaceuticals

Radiopharmaceuticals Diagnostic Imaging Diagnostic Imaging

A Closer Look at Urinary Activity and PET Radiopharmaceuticals for Prostate Cancer Imaging

Diagnostic Imaging

JUNE 28, 2023

In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D.,

Radiopharmaceuticals

Radiopharmaceuticals Nuclear Medicine Imaging

Carolyn J. Anderson, PhD, Receives SNMMI 2024 Georg Charles de Hevesy Nuclear Pioneer Award

Imaging Technology

JUNE 10, 2024

The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2024 Annual Meeting, June 8-11 in Toronto. More recently, she and her collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, recently approved for human studies by the FDA as an Investigational New Drug.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Disease Imaging

Patent Battle Brewing Between Novartis, Lantheus Over Generic Lutathera Radioligand Therapy

Diagnostic Imaging

JANUARY 12, 2024

The FDA has accepted Lantheus' abbreviated new drug application for a generic Lutathera, just months after Novartis announced positive phase 3 data supporting a first-line indication for the radiopharmaceutical in neuroendocrine tumors.

Radiopharmaceuticals

New SNMMI President Cathy Cutler, PhD Discusses Current Challenges and Goals for Nuclear Medicine

Diagnostic Imaging

JUNE 9, 2024

shared her perspective on a number of topics affecting nuclear medicine, ranging from isotope availability and reimbursement challenges for diagnostic radiopharmaceuticals to increasing patient interest in PET imaging. In a recent interview, Cathy Cutler, Ph.D.,

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Diagnostic Imaging

Radiometals for diagnostic imaging and theranostics

Open Medscience

AUGUST 8, 2019

Imaging agents can be used to evaluate organ function, detect cancer, measure blood flow and follow metabolic processes. The post Radiometals for diagnostic imaging and theranostics appeared first on Open Medscience.

Diagnostic Imaging

Diagnostic Imaging Diagnostic Imaging Radiopharmaceuticals

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Health Science

Radiotheranostic Pairs: Bridging Diagnostics and Therapeutics in Cancer

Open Medscience

JUNE 22, 2024

Radiotheranostic Pairs combine diagnostic imaging with targeted radiotherapy, revolutionising personalised cancer treatment through enhanced precision and efficacy. The post Radiotheranostic Pairs: Bridging Diagnostics and Therapeutics in Cancer appeared first on Open MedScience.

Diagnostic

Diagnostic Diagnostic Imaging Imaging Radiopharmaceuticals

Visit TTG Imaging Solutions at ICE 2022

TTG Imaging Solutions

FEBRUARY 17, 2022

About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnostic imaging, and radiopharmaceuticals.

Nuclear Medicine

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging

Illuminating the Future: Recent Breakthroughs in Nuclear Medicine Advancements (Maharashtra, Raigarh, Sangli, Satara, Sindhudurg, Solapur, Thane, Wardha, Washim, Yavatmal)

Future Teleradiology

NOVEMBER 27, 2023

Discuss how these advancements enhance imaging capabilities, providing clearer insights into physiological processes. Discuss how theranostic approaches integrate diagnostic imaging and targeted therapy for more personalized and effective treatments.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Imaging Modalities Radiation

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Health Science

Visit TTG Imaging Solutions at ASNC 2022 Cardiac PET Intensive Virtual Workshop

TTG Imaging Solutions

JANUARY 9, 2022

About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnostic imaging, and radiopharmaceuticals.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Imaging Diagnostic Imaging

Martin B. Shirley Executive Vice President Sales, Marketing & Clinical Operations

TTG Imaging Solutions

AUGUST 1, 2023

Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.

Nuclear Medicine

Nuclear Medicine Clinic Radiopharmaceuticals Diagnostic Imaging

Martin B. Shirley Executive Vice President Sales, Marketing & Clinical Operations

TTG Imaging Solutions

AUGUST 1, 2023

Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.

Nuclear Medicine

Nuclear Medicine Clinic Radiopharmaceuticals Diagnostic Imaging

Visit TTG Imaging Solutions at ASTRO 2021 Annual Meeting

TTG Imaging Solutions

OCTOBER 20, 2021

About TTG Imaging Solutions TTG Imaging Solutions is your partner for nationwide equipment sales, service, parts, turnkey diagnostic imaging, and radiopharmaceuticals. Request a meeting with one of our Regional Sales Managers at sales@ttgimagingsolutions.com.

Radiation Oncology

Radiation Oncology Imaging Radiopharmaceuticals Radiation

Visit TTG Imaging Solutions at ASNC 2021 Virtual Annual Meeting

TTG Imaging Solutions

SEPTEMBER 28, 2021

About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnostic imaging, and radiopharmaceuticals.

Nuclear Medicine

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Blue Earth Diagnostics received U.S.

Diagnostic

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging

Visit TTG Imaging Solutions at ASNC 2021 Cardiac PET Workshop

TTG Imaging Solutions

OCTOBER 27, 2021

About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnostic imaging, and radiopharmaceuticals.

Nuclear Medicine

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging

TTG Imaging Solutions Acquires Digirad Health from Star Equity Holdings

TTG Imaging Solutions

MAY 5, 2023

Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA. Digirad Health, Inc.

Imaging

Imaging Radiopharmaceuticals Radiation Oncology Nuclear Medicine

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

Imaging Technology

APRIL 10, 2024

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,

Radiopharmaceuticals

Radiopharmaceuticals Radiosensitivity Medical Diagnostic

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Imaging Technology

JULY 28, 2023

Precision PET imaging with POSLUMA can help identify the location and extent of prostate cancer, providing clinically valuable information to guide patient management. Blue Earth Diagnostics received U.S. Food and Drug Administration approval for its radiohybrid PET diagnostic imaging product for use in prostate cancer in 2023.

Clinic

Clinic Diagnostic Radiopharmaceuticals Radiation

GE HealthCare Introduces Groundbreaking Developments in Precision Care at SNMMI24

Imaging Technology

JUNE 20, 2024

More than half of the world’s population is underserved and lacks access to essential health services, and two-thirds have no access to diagnostic imaging. Product life extension & upgrades GE HealthCare is also proud to offer global refurbished medical equipment, helping to improve access to affordable, quality healthcare.

Healthcare

Healthcare Healthcare Nuclear Medicine Computed Tomography

The rise of theranostics: Part 3 -- What is a theranostics center?

AuntMinnie

JUNE 3, 2024

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology

TTG Imaging Solutions, LLC Announces Executive Leadership Changes

TTG Imaging Solutions

NOVEMBER 1, 2021

The organization brought a robust customer base in the mid-west along with a strong group of field service engineers The following executive leadership changes are effective November 1, 2021: Jack Tomayko, Ph.D., Remaining in their current roles are John Nalley, EVP of Equipment Service Operations, and Hunter Forestier, VP of Sales and Marketing.

Nuclear Medicine

Nuclear Medicine Imaging Radiopharmaceuticals Medical Imaging

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Imaging Technology

APRIL 3, 2023

produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.

Medical

Medical Radiopharmaceuticals Pharmaceutical Radiation

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

OCTOBER 5, 2023

Nationally recognized clinical oncology guidelines for prostate cancer now include POSLUMA, alongside and for all the same categories as the other currently FDA-approved PSMA PET radiopharmaceuticals.” PET in Men with Newly Diagnosed High-risk Prostate Cancer and Negative Conventional Imaging, ” by Phillip H.

Diagnose

Diagnose Diagnostic Disease Radiation

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 Blue Earth Diagnostics received U.S.

Clinic

Clinic Nuclear Medicine Radiopharmaceuticals Radiation

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 Gauden , D.Phil., 18F-rhPSMA-7.3

Diagnostic

Diagnostic Radiopharmaceuticals Imaging Radiation

Breaking Ground: Exploring the Latest Innovations in the Field of Nuclear Medicine (Madhya Pradesh, Bhopal, Raisen, Rajgarh, Sehore, Vidisha, Morena, Sheopur, Bhind, Gwalior, Ashoknagar)

Future Teleradiology

NOVEMBER 21, 2023

Discuss how PET/CT and PET/MRI combinations offer superior imaging capabilities, providing both anatomical and functional information in a single examination. Advancements in Radiopharmaceuticals: Precision Imaging Agents: Discuss the latest developments in radiopharmaceuticals.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Teleradiology

Diagnostic Imaging Brief

Targeted radiopharmaceuticals offer new hope for longer 'healthspans'

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

What is Radiotheranostics? The Future of Personalised Cancer Diagnosis

A Closer Look at Urinary Activity and PET Radiopharmaceuticals for Prostate Cancer Imaging

Carolyn J. Anderson, PhD, Receives SNMMI 2024 Georg Charles de Hevesy Nuclear Pioneer Award

Patent Battle Brewing Between Novartis, Lantheus Over Generic Lutathera Radioligand Therapy

New SNMMI President Cathy Cutler, PhD Discusses Current Challenges and Goals for Nuclear Medicine

Radiometals for diagnostic imaging and theranostics

The rise of theranostics: Part 1 -- Gaining momentum

Radiotheranostic Pairs: Bridging Diagnostics and Therapeutics in Cancer

Visit TTG Imaging Solutions at ICE 2022

Illuminating the Future: Recent Breakthroughs in Nuclear Medicine Advancements (Maharashtra, Raigarh, Sangli, Satara, Sindhudurg, Solapur, Thane, Wardha, Washim, Yavatmal)

The rise of theranostics: Part 1 -- Gaining momentum

Visit TTG Imaging Solutions at ASNC 2022 Cardiac PET Intensive Virtual Workshop

Martin B. Shirley Executive Vice President Sales, Marketing & Clinical Operations

Martin B. Shirley Executive Vice President Sales, Marketing & Clinical Operations

Visit TTG Imaging Solutions at ASTRO 2021 Annual Meeting

Visit TTG Imaging Solutions at ASNC 2021 Virtual Annual Meeting

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Visit TTG Imaging Solutions at ASNC 2021 Cardiac PET Workshop

TTG Imaging Solutions Acquires Digirad Health from Star Equity Holdings

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

GE HealthCare Introduces Groundbreaking Developments in Precision Care at SNMMI24

The rise of theranostics: Part 3 -- What is a theranostics center?

TTG Imaging Solutions, LLC Announces Executive Leadership Changes

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Breaking Ground: Exploring the Latest Innovations in the Field of Nuclear Medicine (Madhya Pradesh, Bhopal, Raisen, Rajgarh, Sehore, Vidisha, Morena, Sheopur, Bhind, Gwalior, Ashoknagar)

Stay Connected